financetom
Business
financetom
/
Business
/
JPMorgan Picks Executive Jennifer Piepszak to Succeed Departing Chief Operating Officer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JPMorgan Picks Executive Jennifer Piepszak to Succeed Departing Chief Operating Officer
Jan 14, 2025 10:07 AM

12:31 PM EST, 01/14/2025 (MT Newswires) -- JPMorgan Chase ( JPM ) said Tuesday that Daniel Pinto will step down as chief operating officer later this year, with current executive Jennifer Piepszak succeeding him as part of a senior management shuffle.

Pinto, who has been with the lender for more than 40 years, will cease to keep his duties as president and COO as of June 30 and retire at the end of 2026. He will continue to serve as vice chairman at the bank.

Piepszak, who most recently served as co-CEO of JPMorgan's ( JPM ) commercial and investment bank, will become the operating chief with immediate effect. She will assume charge of different areas, including technology, operations and data and analytics functions, while overseeing JPMorgan's ( JPM ) corporate centers in India and the Philippines.

Piepszak and Chief Executive Jamie Dimon will jointly manage all corporate functions at the company, the bank said.

Doug Petno, co-head of global banking, will succeed Piepszak as co-CEO of the commercial and investment bank, alongside current CIB co-CEO Troy Rohrbaugh. John Simmons, head of commercial banking, will take over from Petno as the new co-head of global banking, partnering with Filippo Gori.

JPMorgan ( JPM ) said Marianne Lake and Mary Erdoes will continue in their respective roles as CEO of consumer and community banking and CEO of asset and wealth management.

The lender is scheduled to report its fourth-quarter results on Wednesday. Analysts polled by FactSet expect the bank to report per-share earnings of $4.09 and revenue of $41.91 billion for the quarter.

Price: 243.76, Change: -0.45, Percent Change: -0.18

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mint Closes IPO to Raise $8.05 Million
Mint Closes IPO to Raise $8.05 Million
Jan 13, 2025
02:19 PM EST, 01/13/2025 (MT Newswires) -- Mint (MIMI), a Hong Kong-based interior design and fit-out works provider, said Monday it closed an initial public offering of Class A shares, raising $8.05 million in gross proceeds. The company sold around 2.01 million shares at $4 apiece, including 262,500 shares granted to underwriters for overallotments. Price: 4.37, Change: +0.26, Percent Change:...
Chainalysis Buys Israeli Fraud Detection Startup Alterya for $150M
Chainalysis Buys Israeli Fraud Detection Startup Alterya for $150M
Jan 13, 2025
Blockchain analytics company Chainalysis said Monday it had acquired fraud detection startup Alterya. The deal carried a price tag of $150 million, according to Business Insider. Chainalysis, the largest company tracing illicit crypto flows on behalf of financial institutions and governments, plans to bolster its scam-stopping capabilities with Alterya, CEO Jonathan Levin told CoinDesk. The two companies attack a thematically...
What's Going On With Vera Therapeutics Stock?
What's Going On With Vera Therapeutics Stock?
Jan 13, 2025
Vera Therapeutics Inc ( VERA ) shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. What To Know: Vera Therapeutics ( VERA ) has secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for...
Emergent Gets Contract Option With BARDA for Ebola Treatment
Emergent Gets Contract Option With BARDA for Ebola Treatment
Jan 13, 2025
02:28 PM EST, 01/13/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga. Ebanga is indicated for the treatment of infection caused by Zaire...
Copyright 2023-2026 - www.financetom.com All Rights Reserved